Approach Considerations
See also the Guidelines section for recommendations.
Routine blood tests include complete blood count (CBC), chemistry panel, lipid profile, and thyroid function tests (to exclude thyroid disorders). Routine measurement of blood glucose and hemoglobin A1C (HbA1c) is appropriate in patients with diabetes mellitus. A study by Paynter et al found that models incorporating HbA1c levels significantly improved prediction of cardiovascular disease (CVD) risk among patients with diabetes. [25]
Measurements of lipoprotein(a) (Lp(a)) and coronary calcium scoring provide great value to CVD risk assessment, particularly for lipid-lowering treatment guidance. [26]
Measuring any number of parameters that may reflect coagulation, fibrinolytic status, and platelet aggregability is possible. These measurements may prove to be valuable, but how these measurements affect clinical decision-making is unclear at this time, and including them in routine clinical practice is premature.
The majority of atherosclerotic lesions responsible for the most serious CAD events (that is, the lesions that are most likely to rupture) are mild stenoses of inconsequential hemodynamic significance and are characterized by an abundance of lipid, numerous inflammatory cells, and a thin, fragile fibrous cap. This suggests that although measurements of coronary flow reserve (CFR) and fractional flow reserve (FFR), both of which are discussed below, may be useful in the assessment of the severity of stenoses and in the identification of lesions responsible for effort angina, they are not likely to identify the more dangerous plaques responsible for unstable angina, AMI, and sudden ischemic death.
Screening for cardiovascular risk
Guidelines on screening for cardiovascular risk, released in late 2013 by the American Heart Association/American College of Cardiology (AHA/ACC), recommend use of a revised calculator for estimating the 10-year risk of developing a first atherosclerotic CVD event, which is defined as nonfatal myocardial infarction, death from coronary heart disease, or stroke (fatal or nonfatal) in a person who was initially free from atherosclerotic CVD. [22] The calculator uses a combination of clinical and laboratory risk factors to estimate risk.
For patients 20-79 years of age who do not have existing clinical atherosclerotic CVD, the guidelines recommend assessing clinical risk factors every 4-6 years. For patients with low 10-year risk (< 7.5%), the guidelines recommend assessing 30-year or lifetime risk in patients 20-59 years old.
Regardless of the patient’s age, clinicians should communicate risk data to the patient and refer to the AHA/ACC lifestyle guidelines, which cover diet and physical activity. For patients with elevated 10-year risk, clinicians should communicate risk data and refer to the AHA/ACC guidelines on blood cholesterol and obesity.
Screening for coronary heart disease
In 2015, the American College of Physicians (ACP) released guidelines on screening for coronary heart disease, including the following [27] :
-
There is no evidence that cardiac screening improves patient outcomes in asymptomatic, low-risk adults.
-
Potential harms of cardiac screening include false-positive results causing patients to undergo potentially unnecessary tests and procedures.
-
Among adults at low risk, prevalence of coronary heart disease is low, and cardiac screening is of low predictive value. Therefore, cardiac screening is of low yield, and the probability that positive findings will influence therapeutic decision making is low.
-
Clinicians should therefore emphasize strategies to reduce cardiovascular risk even further among low-risk adults by treating modifiable risk factors (smoking, diabetes, blood pressure, hyperlipidemia, overweight, and exercise).
-
Clinicians should not screen asymptomatic, low-risk adults for cardiac disease using resting or stress electrocardiography, stress echocardiography, or stress myocardial perfusion imaging.
-
Clinicians should conduct cardiovascular risk assessment with a global risk score combining individual risk factor measurements into a single quantitative estimate of risk.
-
The ACP recommendations do not apply to symptomatic patients or to screening athletes before participation in various events.
Screening for cardiovascular risk without measuring cholesterol
A screening strategy for calculating cardiovascular risk that uses multiple non–laboratory-based risk markers performed as well as approaches based on Framingham risk scores, which use cholesterol measurements in all patients. The analysis was conducted using data on 5998 adults in the National Health and Nutrition Examination Survey (NHANES) III. The risk markers included age, sex, smoking status, history of diabetes, blood-pressure treatment, systolic blood pressure, and body mass index. [28, 29]
With the multistage-screening approach, patients deemed high risk would be treated with statins, those deemed low risk would be monitored without treatment, and intermediate-risk patients would undergo laboratory testing of cholesterol levels. There was no significant difference between the multistage approach and the Framingham risk score approach in discriminating risk. [28, 29]
The multistage screening strategy was also more cost effective than the Framingham approach. The incremental cost-effective ratio was $52,000 per quality-adjusted life-year (QALY) for men and $83,000 per QALY for women, compared with more than $300,000 per QALY with the Framingham approach. [28, 29]
Fractional Flow Reserve
Myocardial FFR has been used as an index of functional severity of coronary artery stenosis. FFR represents the fraction of the normal maximal coronary flow that can be achieved in an artery in which flow is restricted by a coronary stenosis. The concept of FFR is based on the observation that myocardial perfusion is entirely pressure dependent during maximal hyperemia.
Maximal blood flow in the presence of a stenosis is therefore determined by the driving pressure distal (Pd) to the stenosis, whereas the theoretical normal maximal blood flow is determined by the pressure proximal (Pp) to the stenosis. FFR is calculated during maximal hyperemia (obtained with adenosine or papaverine) as FFR = Pd/Pp. FFR less than 0.75 is typically associated with other objective evidence of myocardial ischemia. FFR is calculated from the ratio of the mean pressure distal to a coronary stenosis to the mean aortic pressure during maximal hyperemia. If the FFR is less than 0.75, sensitivity is at least 80% and specificity is at least 85% for the presence of ischemia on noninvasive stress testing.
Lipid Studies
Fasting lipid profile includes the following [30, 31, 32] :
-
Total cholesterol level
-
LDL cholesterol (LDL-C) level
-
HDL cholesterol (HDL-C) level
-
Triglyceride level
Specific lipid studies (if necessary) include the following:
-
Small, dense LDL-C level
-
Lipoprotein (a) level
-
Apoprotein profile
-
Direct measurement of HDL-C
C-Reactive Protein
In 2013, ACC/AHA Risk Assessment commented on use of newer risk markers after quantitative risk assessment. [33] The opinion of this expert committee was that quantitative risk assessment should occur first, and if a risk-based treatment decision is uncertain, assessment of family history of CVD, hs-CRP, coronary artery calcium score, or ankle-brachial index may be considered to inform treatment decision making. The committee did not recommend routine measurement of carotid intima-media thickness for risk assessment a first atherosclerotic CVD event. The committee also did not recommend use of ApoB, chronic kidney disease, albuminuria, or cardiorespiratory fitness evaluation for risk assessment for a first atherosclerotic CVD event.
Serum Markers
Serum markers in patients with suspected acute cardiac events (ACS, MI) include the following:
-
Troponins (I or T)
-
Creatine kinase with MB isozymes
-
Lactate dehydrogenase and lactate dehydrogenase isozymes
Biomarkers
In a 10-year comparison of 10 biomarkers for predicting death and first major cardiovascular events in approximately 3000 individuals, the most informative biomarkers for predicting death were the following [34] :
-
CRP
-
Renin
-
Urinary albumin-to-creatinine ratio
The most informative biomarkers for predicting major cardiovascular events were B-type natriuretic peptide and the urinary albumin-to-creatinine ratio. Individuals with elevated multimarker scores had a risk of death 4 times higher and a risk of major cardiovascular events almost 2 times higher than those with low multimarker scores. However, the use of multiple biomarkers added only moderately to the overall prediction of risk based on conventional cardiovascular risk factors.
In a study that evaluated four potential biomarkers of endothelial health in 34 patients with mature collateral networks who successfully underwent percutaneous coronary intervention (PCI) for chronic total coronary occlusion (CTO) before the procedure and 6-8 postsurgery, there were no signficant changes in system levels of sICAM-1, sE-selectin, microparticles, or tissue factor 6-8 weeks following PCI. [35] Although the investigators noted an association between estimated retrograde collateral flow before the CTO recanalization and these four biomarkers, they attributed this relationship as being associated with an ability to develop collaterals as opposed to their presence and extent.
Echocardiography
Transthoracic echocardiography helps to assess left ventricular function, wall-motion abnormalities in the setting of ACS or AMI, and mechanical complications of AMI.
Transesophageal echocardiography is most often used for assessing possible aortic dissection in the setting of AMI. Stress echocardiography can be used to evaluate hemodynamically significant stenoses in stable patients who are thought to have CAD. Treadmill echocardiography stress testing and dobutamine echocardiography stress testing provide equivalent predictive values. ECG findings are depicted below.
Coronary Artery Atherosclerosis. Stress test, part 1. Resting electrocardiogram showing normal baseline ST segments. (See the image below for part 2.)
Coronary Artery Atherosclerosis. Stress test, part 2. Stress electrocardiogram showing significant ST-segment depression. (See the image above for part 1.)
Nuclear Imaging Studies
These studies are useful in assessing patients for hemodynamically significant coronary artery stenoses. Stress and rest nuclear scintigraphic studies using thallium, sestamibi, or teboroxime are sometimes helpful.
Types of nuclear imaging stress tests include a treadmill nuclear stress test, a dipyridamole (Persantine) or adenosine nuclear stress test, and a dobutamine nuclear stress test. Stress nuclear imaging findings are depicted below.
Coronary Artery Atherosclerosis. Stress nuclear imaging showing anterior, apical, and septal wall perfusion defects during stress, which are reversible as observed on the rest images. These defects strongly suggest the presence of significant stenosis in the left anterior descending coronary artery.
Radionuclide stress myocardial perfusion imaging can be used to quantify CFR. Thallium-201 (201 Tl) or sestamibi are widely used for this. Flow reserve is typically assessed during exercise or with pharmacologic coronary vasodilators.
MI-avid scintigraphy may be indicated for detection and localization of infarcted myocardium if evidence from other tests is inconclusive.
Computed Tomography
Multidetector computed tomography (MDCT) can allow excellent visualization of the coronary arteries, but its relatively high radiation dose is one of the limitations of this approach. Newer generations of CT scanners may be able to reduce the required radiation exposure to make this technology more promising for screening asymptomatic patients. Low-dose CT attenuation correction (CTAC), which is performed for hybrid positron emission tomography (PET)/CT and single-photon emission computed tomography (SPECT)/CT myocardial perfusion imaging (MPI) can visually assess coronary artery calcium with high agreement with the Agatston score (AS). [36] These scans should routinely be assessed for visually estimated coronary artery calcium.
However, guidelines that address the use of CAD imaging tests may disagree. A study by Ferket, et al found several guidelines for risk assessment of asymptomatic CAD to have conflicting recommendations. [37] More research, especially randomized controlled trials, are needed in order to establish the actual impact imaging has on clinical outcomes.
A meta-analysis by Bamberg et al concluded that coronary CT angiography is an important tool in detecting the presence and extent of CAD and independent predictors of significant coronary stenosis and other cardiovascular events. [38] Glineur et al found that preoperative angiography predicts graft patency in the right gastroepiploic artery and right internal thoracic artery, whereas the flow pattern in saphenous vein grafts is significantly less influenced by quantitative angiographic parameters. [39]
The successful use of coronary CT angiography in the Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter (CONFIRM) Registry study suggests that this modality may provide a suitable alternative to cardiac stress testing and conventional angiography in the evaluation of patients with a low to intermediate cardiovascular disease risk. [23]
Plaque characteristics on CT angiography appear to help identify high-risk coronary lesions. In a study addressing the use of CT angiography to detect and characterize coronary plaques prone to rupture, Maurovich-Horvat et al identified several features that were associated with vulnerable plaques. [40, 41] Such high-risk features included large plaque volume, low CT attenuation, the “napkin-ring sign,” positive remodeling, and spotty calcification.
The investigators’ findings suggest that coronary CT angiography can be effectively used in this setting for purposes beyond simply ruling out coronary stenosis. [40, 41] For this modality to achieve optimal prognostic value in the identification of high-risk plaques, however, quantitative and qualitative plaque characteristics (eg, plaque volume and the napkin-ring sign) should be combined with functional measures (eg, fractional flow reserve).
Min et al suggest patients with CAD have an increased mortality risk that was highest among those with 3-vessel disease or left main disease. Conversely, the lack of CAD portended a good prognosis. [42]
Electron Beam Computed Tomography
Electron beam CT (EBCT) is a relatively new, noninvasive method of evaluating calcium content in the coronary arteries. Healthy coronary arteries lack calcium. As atherosclerotic plaques grow, calcium accumulates because of a perpetuating inflammatory process or the healing and scarring induced by this process. EBCT is currently used as a screening test in asymptomatic patients and as a diagnostic test for obstructive CAD in symptomatic patients, although experts in the field have reached no consensus regarding indications for its use.
EBCT has been demonstrated to have high sensitivity, with an overall predictive accuracy of 70%, according to the American College of Cardiology (ACC)/American Heart Association (AHA) Expert Consensus Document. [43] However, it has low specificity (ie, a substantial false-positive rate), which raises the index of suspicion for CAD and leads to expensive and unwarranted additional testing to exclude CAD. Consequently, the ACC/AHA report did not recommend EBCT scanning to help diagnose obstructive CAD.
Whether EBCT is a worthwhile tool for screening of CAD is still unclear. Well-established clinical indicators, such as the Framingham risk score and the National Cholesterol Education Program (NCEP) risk calculator, already accurately predict the likelihood of CAD. Whether EBCT adds to these indicators has yet to be shown. The Multi-Ethnic Study of Atherosclerosis (MESA), sponsored by the US National Institutes of Health, has been assessing prospective evaluation of EBCT in asymptomatic subjects to answer this question. [44]
EBCT may have niche uses, including (1) determination of whether individuals who appear to be at intermediate risk are really at a higher risk (eg, asymptomatic elderly patients who have high calcium scores) and (2) determination of a low likelihood of significant CAD if EBCT demonstrates a low or absent calcium score.
Optical Coherence Tomography Imaging
Optical coherence tomography (OCT) imaging is a method of catheter-based, high-resolution intravascular imaging. Unlike IVUS, it measures the backreflection of infrared light rather than sound. The main advantage of OCT is its remarkable resolution, which is in the range of 10-20 µm. In addition, acquisition rates are near video speed, an advantage relative to many other technologies for assessing plaque. In contrast to IVUS scanning, the typical OCT catheters contain no transducers within their frame, which makes them small and inexpensive. Because OCT imaging uses light, a variety of spectroscopic techniques are available, including polarization spectroscopy, absorption spectroscopy, elastography, OCT Doppler, and dispersion analysis.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) may be used to gain information noninvasively about blood vessel wall structure and to characterize plaque composition. In a study of 393 men and 235 women with suspected CAD, Greenwood et al found that cardiovascular magnetic resonance (CMR) had significantly higher diagnostic sensitivity than SPECT in both sexes (P< 0.0001). [45]
The sensitivity of CMR was similar in males and females (85.6% vs 88.7%; P = 0.57), whereas that of SPECT was significantly higher in males than in females (70.8% vs 50.9%; P = 0.007). [45] The specificity of CMR (82.8% in males vs 83.5% in females; P = 0.86) was comparable to that of SPECT (81.3% in males vs 84.1% in females; P = 0.48).
Positron Emission Tomography
For the diagnosis of obstructive CAD, rubidium-82 (82 Rb) PET appears superior to technetium-99m (99m Tc)–based SPECT. In a systematic review of studies that used82 Rb PET or99m Tc SPECT, with coronary angiography as a reference standard, PET and SPECT had sensitivities of 90% and 85%, respectively, and specificities of 88% and 85%, respectively. PET had even greater superiority when patients with low likelihood ratio were excluded. [46]
Although the approximate estimated cost per scan is higher with PET than with SPECT ($1850 versus $1000), radiation exposure was estimated to be 4- to 5-fold lower with PET. [46] In addition, PET offers better spatial and temporal resolution and shorter imaging time. [47]
One study has shown that assessment with PET is a powerful, independent predictor of cardiac mortality in patients with known or suspected coronary artery disease and provides meaningful incremental risk stratification over clinical and gated myocardial perfusion imaging variables. [48]
Coronary Angiography
Coronary angiography was the first available in vivo assessment of the coronary arteries. In this technique, an iodinated contrast agent is injected through a catheter placed at the ostium of the coronaries. The contrast agent is then visualized through radiographic fluoroscopic examination of the heart.
Coronary angiography remains the criterion standard for detecting significant flow-limiting stenoses that may be revascularized through percutaneous or surgical intervention (as seen in the image below).
Coronary Artery Atherosclerosis. Cardiac catheterization and coronary angiography in the left panel shows severe left anterior descending coronary artery stenosis. This lesion was treated with stent placement in the left anterior descending coronary artery, as observed in the right panel.
Quantitative coronary angiography (QCA) is used to perform computerized quantitative analysis of the entire coronary tree and has been widely employed in many trials of atherosclerotic progression and regression.
Coronary angiography has several limitations. Severity of stenosis is generally estimated visually, but estimation is limited by the fact that interobserver variability may range from 30-60%. The presence of diffuse disease may also lead to underestimation of stenoses, because the stenosed areas are expressed as a percent of luminal diameter compared with adjacent normal coronary segments, and, in diffuse disease, no such segments are noted. This usually occurs in diabetic patients, in whom coronary arteries are traditionally described as small-caliber vessels, when that appearance is actually due to the presence of diffuse symmetrical involvement of the entire vessel, as elucidated by IVUS studies.
One of the other limitations of coronary angiography is that only the vessel space occupied by blood is visualized. The actual extent of atherosclerotic plaque volume in the wall cannot be assessed with this technique.
Angiography does not provide information about plaque burden, which may be significant due to positive remodeling of the plaque, even when the degree of luminal obstruction is mild.
Because of the inherent limitations of coronary angiography, attention has been directed toward using physiologic approaches to determine the severity of coronary stenoses. The commonly used methods of measuring human coronary blood flow in the cardiac catheterization laboratory are Doppler velocity probes (for measuring CFR) and pressure wires (for measuring FFR). Although most current methods measure relative changes in coronary blood flow, useful information about the physiologic significance of stenosis, cardiac hypertrophy, and pharmacologic interventions can be obtained from these measurements.
Through the Prospective Multicenter Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve (DISCOVER-FLOW) Study, Koo et al created a novel technique to noninvasively assess fractional flow reserve, using coronary CT angiograms (CTA). They analyzed 159 vessels in 103 patients. All patients underwent cardiac CTA, invasive angiography fractional flow reserve (FFR), and CT-FFR. FFR-CT and CTA were compared with invasive FFR as the criterion standard. In a per-vessel basis, the accuracy, sensitivity, specificity, positive predictive value, and negative predictive value were 84.3%, 87.9%, 82.2%, 73.9%, 92.2%, respectively, for FFRCT. For cardiac CTA stenosis, they were 58.5%, 91.4%, 39.6%, 46.5%, 88.9%, respectively. This technique, if widely available, may be immensely useful because CTA, although easily interpreted in terms of presence or absence of disease, can be difficult to interpret with regards to severity of disease. [49]
Doppler Velocity Probes
Doppler velocity probes use a Doppler flow meter, which is based on the principle of the Doppler effect. This is the most widely applied technique for measuring coronary flow in humans. High-frequency sound waves are reflected from moving red blood cells and undergo a shift in sound frequency proportional to the velocity of the blood flow.
In pulsed-wave Doppler methods, a single piezoelectric crystal can transmit and receive high-frequency sound waves. These methods have been successfully applied in humans by using miniaturized crystals fixed to the tip of catheters. Technological developments have further miniaturized steerable 12-MHz Doppler guide wires to a diameter of 0.014 inches. Flow to a stenosis can therefore be assessed distally and proximally. The Doppler guidewire measures phasic flow velocity patterns and tracks linearly with flow rates in small, straight coronary arteries.
Indications for Doppler velocity probe use include determining the severity of intermediate stenosis (40-60%) and evaluating whether normal blood flow has been restored after percutaneous transluminal coronary angioplasty (PTCA).
The use of smaller Doppler catheters allows measurement of selective coronary artery flow velocity. By noting the increase in flow velocity following administration of a strong coronary vasodilator, such as papaverine or adenosine, the CFR can be defined. CFR provides an index of the functional significance of coronary lesions that obviates some of the ambiguity of anatomical description.
The current Doppler probe method has limitations. Limitations include the following:
-
Only changes in flow velocity, rather than absolute velocity or volumetric flow, are measurable
-
The change in flow velocity is directly proportional to changes in volumetric flow only when vessel dimensions are constant at the site of the sample volume
-
Other factors, including left ventricular hypertrophy and myocardial scarring, can also affect CFR
-
Changes in luminal diameter and arterial cross-sectional area during interventions are not reflected in measurements of flow velocity, thus potentially causing underestimation of the true volume flow
Because this technique does not measure absolute coronary blood flow, several indices of flow velocity have been used for assessing the physiologic significance of coronary stenoses. Coronary flow velocity reserve is the ratio of maximum flow velocity to baseline flow velocity.
Patients with a coronary flow velocity ratio of less than 2 typically have other corroborating evidence of myocardial ischemia and improve symptomatically with revascularization. Conversely, patients with a ratio of more than 2 usually lack other objective evidence of myocardial ischemia and have a favorable outcome with conservative management; therefore, flow velocity measurements can be helpful in the treatment of patients with coronary lesions of intermediate severity.
Relative coronary flow reserve
Relative CFR is calculated as follows: ([rCFR] = CFR target/CFR reference). Relative CFR involves Doppler coronary flow measurements of target and reference vessel CFR with a Doppler-tipped guidewire. In one report, El-Shafei et al found that, compared with patients who had negative stress-imaging study findings, patients who had positive stress-study findings showed more angiographically severe stenoses (74% +/- 13% vs 44% +/- 24%) with lower target CFRs (1.68 +/- 0.55 vs 2.46 +/- 0.74) and lower rCFRs (0.72 +/- 0.22 vs 1 +/- 0.26). [50]
Based on cut points (CFR >1.9; rCFR >0.75), compared with CFR, rCFR had similar agreement (kappa 0.54 vs 0.5), sensitivity (63% vs 71%), specificity (88% vs 83%), and positive predictive value (83% vs 81%) with myocardial perfusion tomography.
Although rCFR, as with CFR, correlates with stress myocardial perfusion imaging results, rCFR did not have significant incremental prognostic value over CFR alone for myocardial perfusion imaging. However, rCFR does provide additional information regarding the status of the microcirculation in patients with CAD and complements the CFR for lesion assessment.
Ultrasonography
Ultrasonography aids in evaluating brachial artery reactivity and carotid artery intima media thickness, which are measures of vessel wall function and anatomy, respectively. These evaluations remain research techniques at this time but hold promise as reliable noninvasive, and therefore repeatable, measures of disease and surrogate endpoints for the evaluation of therapeutic interventions.
Brachial Artery Reactivity
The loss of endothelium-dependent vasodilation is a feature of even the early stages of atherosclerosis. The availability of high-resolution ultrasonographic systems makes the visualization and measurement of small peripheral conduit vessels, such as the human brachial artery, possible. Flow-mediated dilation of the brachial artery has been pioneered as a means of evaluating the health and integrity of the endothelium. The healthy endothelium dilates in response to an increase in blood flow, whereas vessels affected by atherosclerosis do not dilate and may paradoxically constrict.
Carotid artery intima-media thickness
B-mode ultrasonography of the common and internal carotid arteries is a noninvasive measure of arterial wall anatomy that may be performed repeatedly and reliably in asymptomatic individuals. The combined thickness of the intima and media of the carotid artery is associated with the prevalence of cardiovascular risk factors and disease and an increased risk of myocardial infarction and stroke. This association is at least as strong as the associations observed with traditional risk factors.
Intravascular Ultrasonography
IVUS demonstrates the luminal dimensions and, more importantly, the tissue composition of the vascular wall in tomographic subsegments that can be summated to create a 3-dimensional picture showing arterial remodeling and the diffuseness of atherosclerosis with clarity unobtainable by angiography.
IVUS delineates vascular remodeling—positive and negative. Positive remodeling shows adaptive outward expansion of the external elastic membrane to accommodate growing plaques (Glagov phenomenon). Negative remodeling exhibits discrete areas of vascular luminal encroachment by the ingrowing plaques.
Positive remodeling is more commonly associated with unstable angina, whereas negative remodeling is associated with stable angina, according to an IVUS study of 85 patients by Schoenhagen and colleagues. [51]
The apparently paradoxical findings of angiographic studies suggesting that AMI most often occurs in less than 50% of stenosed arterial segments, and those of autopsy studies showing AMI to be associated with large plaques, are reconciled by IVUS findings. IVUS shows the responsible lesions to be large plaques that have positively remodeled, thus causing minimal luminal encroachment and exhibiting echolucency suggesting a lipid-rich pool in the plaque center.
The ability of IVUS to identify positively remodeled plaques and the presence of diffuse disease in some ways makes it better than angiography, the less-than-perfect criterion standard. IVUS can much more clearly demonstrate the presence or absence of fibrosis, calcium, and ulceration, as well as eccentricity of the plaques.
Ostial lesions can also be better defined by IVUS.
Histology
A system devised by Stary et al classifies atherosclerotic lesions according to their histologic composition and structure. [8]
In a type I lesion, the endothelium expresses surface adhesion molecules E selectin and P selectin, attracting more polymorphonuclear cells and monocytes in the subendothelial space.
In a type II lesion, macrophages begin to take up large amounts of LDL (fatty streak).
In a type III lesion, as the process continues, macrophages become foam cells.
In a type IV lesion, lipid exudes into the extracellular space and begins to coalesce to form the lipid core.
In a type V lesion, SMCs and fibroblasts move in, forming fibroatheromas with soft inner lipid cores and outer fibrous caps.
In a type VI lesion, rupture of the fibrous cap with resultant thrombosis causes ACS.
As lesions stabilize, they become fibrocalcific (type VII lesion) and, ultimately, fibrotic with extensive collagen content (type VIII lesion).
-
Coronary Artery Atherosclerosis. Stress test, part 1. Resting electrocardiogram showing normal baseline ST segments. (See the image below for part 2.)
-
Coronary Artery Atherosclerosis. Stress test, part 2. Stress electrocardiogram showing significant ST-segment depression. (See the image above for part 1.)
-
Coronary Artery Atherosclerosis. Stress nuclear imaging showing anterior, apical, and septal wall perfusion defects during stress, which are reversible as observed on the rest images. These defects strongly suggest the presence of significant stenosis in the left anterior descending coronary artery.
-
Coronary Artery Atherosclerosis. Cardiac catheterization and coronary angiography in the left panel shows severe left anterior descending coronary artery stenosis. This lesion was treated with stent placement in the left anterior descending coronary artery, as observed in the right panel.
-
Coronary Artery Atherosclerosis. The illustrations depict vulnerable plaque and the mechanism of plaque rupture.
-
Coronary Artery Atherosclerosis. Positive and negative arterial remodeling are illustrated.
-
Coronary Artery Atherosclerosis. Low power, hematoxylin and eosin (H&E) stain of an atheromatous plaque of the coronary artery. The wall is thickened, and no internal or external elastic lamina is seen. There is a thick fibrous cap containing some neovascularization in the lower left of the image.
-
Coronary Artery Atherosclerosis. Low power, hematoxylin and eosin (H&E) stain of an atheromatous plaque of the coronary artery. There is marked luminal narrowing. The fibrous cap on the left contains a central lipid core containing macrophages and cholesterol clefts (lower center). Calcification (dark purple) is seen on the right.
-
Coronary Artery Atherosclerosis. This image is from a patient with an acute anterolateral myocardial infarction who developed cardiogenic shock. Coronary angiography images showed severe stenosis of the left anterior descending coronary artery, which was dilated by percutaneous transluminal coronary angioplasty.
Tables
| Group | Recommendation | |
|---|---|---|
| 1. | Age ≥21 years with clinical ASCVD (including history of or current acute coronary syndrome, myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, PAD presurmed to be of atherosclerotic origin) | 1.For patients age >75 years, high-intenstiy statin(or moderate-intensity statinif not candidate for high-intensity due to safety concerns) 2. For patients age >75 years, moderate-intensity statin |
| 2. | Adults aged ≥21 years with LDL-C ≥190 mg/dl (not due to modifiable | 1. High-intensity statin therapy to achieve ≥50% reduction in LDL-C statin (or moderate-intenstiy if not a candidate for high-intensity statin due to safety concerns) 2. May consider combining statin and non-statin therapy to further reduce LDL-C 3. Cascade screeing of close biologic relatives should be performed to identify others with the disease who would benefit from treatment. |
| 3. | Adults aged 40-75 years without ASCVD but with diabetes and with LDL-C 70-189 mg/dL | 1. Moderate-intensity statin 2. If 10-year ASCVD risk ≥7.5%, consider high-intensity statin. |
| 4. | Adults aged 40-75 years without ASCVD or diabetes, and with LDL-C 70-189 mg/dL and an estimated 10 year risk for ASCVD of ≥7.5% | 1. Estimate 10-year ASCVD risk using Pooled Cohort Equations a. if ≥7.5%, moderate- or high-intensity statin; b. If ≥to < 7.5%, consider moderate-intensity statin. 2. If selected individuals with 10-year ASCVD risk < 5%, or age < 40 or > 75 years, individualize decisions based on presence of other high-risk features. 3. Before initiation of statin therapy for primary prevention, it is reasonable for clinicians and patients to engage in a discussion that considers the potential for ASCVD risk-reduction benefits and for adverse effects and drug-drug interactions, as well as patient preferences for treatment. |
ASCVD = atherosclerotic cardiovascular disease; LDL-C = low-density lipoprotein cholesterol; PAD = peripheral artery disease; TIA = transient ischemic attack. |
||
What would you like to print?
- Overview
- Presentation
- DDx
- Workup
- Approach Considerations
- Fractional Flow Reserve
- Lipid Studies
- C-Reactive Protein
- Serum Markers
- Echocardiography
- Nuclear Imaging Studies
- Computed Tomography
- Electron Beam Computed Tomography
- Optical Coherence Tomography Imaging
- Magnetic Resonance Imaging
- Positron Emission Tomography
- Coronary Angiography
- Doppler Velocity Probes
- Ultrasonography
- Histology
- Show All
- Treatment
- Approach Considerations
- Preventive Strategies
- Treatment of Low HDL levels and High Triglyceride levels in Patients With Diabetes
- ACE Inhibitors to Reduce Blood Pressure
- Antiplatelet Agents for Acute Coronary Events
- Pharmacologic Treatment of Angina
- Hormone Therapy Concerns
- Antibiotic Therapy in Coronary Artery Atherosclerosis
- Revascularization Procedures
- European Society of Cardiology Guidelines
- Lifestyle Changes
- Additional Therapies for Atherosclerosis
- Stable Coronary Artery Disease after Intervention
- Consultations
- Show All
- Guidelines
- Medication
- Questions & Answers
- Media Gallery
- Tables
- References
